Nasdaq · Biotech stocks database

BLTE — Belite Bio Inc

BLTE (Belite Bio Inc) stock: $170.96, $6.88B market cap, $352.9M cash, $6.53B EV, $8.01B fully diluted market cap. Next expected readout: Jun-27. Lead program: Tinlarebant (Geographic Atrophy), Phase 3. Data from Fully Diluted's biotech stocks database.

Share price

$170.96

Market cap

$6,884.9M

Cash

$352.9M

Enterprise value

$6,532.0M

Balance sheet

Cash	$352.9M
Debt	$0.0M
Net cash	$352.9M
Enterprise value	$6,532.0M
Basic shares	40.3M shares
Fully diluted shares	46.8M shares
Fully diluted market cap	$8,006.8M
Cash per share	$8.76

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading BLTE daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 11 - Sep 22	Tinlarebant	Phase 3	Geographic Atrophy	—
Mar 14 - Apr 25	Tinlarebant	Phase 3	STGD1; Stargardt Disease 1	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	Tinlarebant
Lead indication	Geographic Atrophy
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05949593	Phase 3	Active, not recruiting	Sponsor	BLTE	—	Geographic Atrophy	—
NCT06388083	Phase 3	Active, not recruiting	Sponsor	BLTE	—	STGD1; Stargardt Disease 1	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Belite Bio, Inc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	715,332	no change	0.94%	2026-08-14
Logos Global Management	250,000	+250,000	1.66%	2026-08-14
OrbiMed Advisors	13,300	+13,300	0.04%	2026-08-14
ADAR1 Capital Management	0	-26,880	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego